[go: up one dir, main page]

PH12023552974A1 - Combination therapies - Google Patents

Combination therapies

Info

Publication number
PH12023552974A1
PH12023552974A1 PH1/2023/552974A PH12023552974A PH12023552974A1 PH 12023552974 A1 PH12023552974 A1 PH 12023552974A1 PH 12023552974 A PH12023552974 A PH 12023552974A PH 12023552974 A1 PH12023552974 A1 PH 12023552974A1
Authority
PH
Philippines
Prior art keywords
effective amount
therapeutically effective
combination therapies
combinations
formula
Prior art date
Application number
PH1/2023/552974A
Inventor
Balpreet Bhogal
Wei Cai
Xuedong Dai
Nicolas Freddy J Darville
Nikki Daskalakis
Xiangjun Deng
Lichao Fang
Lucille Angela Ferrante
Liqiang Fu
Christina Diane Guttke
Min Chul Kwon
Ming Li
Lianzhu Liu
Yingtao Liu
Alicia Tee Fuay Ng
Kathryn Elizabeth Packman
Vineet Pande
Ulrike Philippar
Eva Christine Pietsch
Olivier Alexis Georges Querolle
Yu Sun
Johannes Wilhelmus J Thuring
Tinne Ann J Verhulst
Yanping Xu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PH12023552974A1 publication Critical patent/PH12023552974A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of a BCL-2 inhibitor; and optionally, a therapeutically effective amount of at least one other antineoplastic agent. Also disclosed are methods for treating a subject who has been diagnosed with a hematopoietic disorder using such combinations. Compounds are represented by Formula (I) as follows: wherein R 1a, R 1b, R 2, R 3, R 4, U, Y 1, X 1, X 2, n1, n2, n3 and n4 are defined herein.
PH1/2023/552974A 2021-05-11 2022-05-09 Combination therapies PH12023552974A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2021093036 2021-05-11
CN2021100523 2021-06-17
CN2022086004 2022-04-11
PCT/CN2022/091679 WO2022237720A1 (en) 2021-05-11 2022-05-09 Combination therapies

Publications (1)

Publication Number Publication Date
PH12023552974A1 true PH12023552974A1 (en) 2024-03-11

Family

ID=81753154

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2023/552974A PH12023552974A1 (en) 2021-05-11 2022-05-09 Combination therapies

Country Status (16)

Country Link
EP (1) EP4337216A1 (en)
JP (1) JP2024518497A (en)
KR (1) KR20240006631A (en)
CN (2) CN117460513A (en)
AU (1) AU2022274071A1 (en)
CA (1) CA3215313A1 (en)
CL (2) CL2023003239A1 (en)
CO (1) CO2023014322A2 (en)
DO (1) DOP2023000246A (en)
IL (1) IL308335A (en)
MX (1) MX2023013410A (en)
PE (1) PE20240593A1 (en)
PH (1) PH12023552974A1 (en)
TW (1) TW202308643A (en)
UY (1) UY39761A (en)
WO (1) WO2022237720A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024114664A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
CN120282784A (en) * 2022-11-30 2025-07-08 詹森药业有限公司 Combination comprising a multiple endocrine oncoprotein-MLL inhibitor and a BCL-2 inhibitor
WO2024218072A1 (en) * 2023-04-17 2024-10-24 Janssen Pharmaceutica Nv Combination of a menin-ll1 inhibitor, a dna intercalating agent and a pyrimidine analogue to treat a hematopoietic disorder.
WO2025082444A2 (en) * 2023-10-20 2025-04-24 Janssen Pharmaceutica Nv (r) -n-ethyl-5-fluoro-n-isopropyl-2- ( (5- (2- (6- ( (2-methoxyethyl) (methyl) amino) -2-methylhexan-3-yl) -2, 6-diazaspiro [3.4] octan-6-yl) -1, 2, 4-triazin-6-yl) oxy) benzamide, formulations and dosage regimens thereof, for use in treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017013149B1 (en) 2014-12-18 2022-10-11 Takeda Pharmaceutical Company Limited COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF
KR20180103053A (en) * 2015-12-22 2018-09-18 비타이 파마슈티컬즈, 인코포레이티드 Inhibitors of Menin-MLL Interactions
EP3805215A1 (en) * 2016-06-10 2021-04-14 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction
TW202104207A (en) 2019-04-17 2021-02-01 美商健生生物科技公司 Dihydroorotate dehydrogenase inhibitors
UA129208C2 (en) 2019-12-19 2025-02-05 Янссен Фармацевтика Нв SUBSTITUTED STRAIGHT CHAIN SPIRODERIVATIVES

Also Published As

Publication number Publication date
CO2023014322A2 (en) 2023-11-20
TW202308643A (en) 2023-03-01
CL2024002832A1 (en) 2025-02-14
UY39761A (en) 2022-11-30
AU2022274071A1 (en) 2024-01-04
KR20240006631A (en) 2024-01-15
DOP2023000246A (en) 2024-04-30
CN118845787A (en) 2024-10-29
MX2023013410A (en) 2023-12-06
CA3215313A1 (en) 2022-11-17
WO2022237720A1 (en) 2022-11-17
PE20240593A1 (en) 2024-03-21
IL308335A (en) 2024-01-01
CN117460513A (en) 2024-01-26
EP4337216A1 (en) 2024-03-20
JP2024518497A (en) 2024-05-01
CL2023003239A1 (en) 2024-06-07

Similar Documents

Publication Publication Date Title
PH12023552974A1 (en) Combination therapies
MX2022006986A (en) Kras g12c inhibitors.
PH12022553378A1 (en) Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
EP4356975A3 (en) Erbb/btk inhibitors
MX2010007375A (en) Novel lupane derivatives.
PT2038290E (en) Modulators of toll-like receptor 7
MX2022006533A (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof.
WO2024026433A3 (en) Novel dpp1 inhibitors and uses thereof
MX2019011506A (en) Combinations of chk1- and wee1 - inhibitors.
MX2023013436A (en) COMBINATION THERAPIES.
MX2024003770A (en) Imidazopyridazine il-17 inhibitor compounds.
ZA202212095B (en) Il4i1 inhibitors and methods of use
MX2024002409A (en) CANCER THERAPIES.
MX2024003772A (en) Imidazopyridazine il-17 inhibitor compounds.
MX2024008358A (en) Medicine for treating or preventing cancer.
MX2022003845A (en) Medicinal cognitive treatments.
MX2023005530A (en) Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer.
MX2024000610A (en) Therapeutic compounds and methods.
CO2022002670A2 (en) Method to block or ameliorate cytokine release syndrome
WO2018005444A3 (en) Methods for treating cancer
MX2023012678A (en) Modulators of trex1.
PH12023553004A1 (en) Modulators of trex1
NZ791481A (en) Immunomodulating urea azalides
PH12021553304A1 (en) Compounds and methods of use thereof as antibacterial agents
MX2022007625A (en) Combinations.